Results 61 to 70 of about 642,659 (199)

Trends in PCSK9 Inhibitor Utilization in the United States, Europe and Other Countries: An Analysis of International Sales Data [PDF]

, 2022
First approved in July 2015, proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors are costly lipid-lowering drugs. Their utilization has important policy and clinical implications but has not been assessed across different geographical ...
Wong, Ian, Knapp, M, Blais, JE, Chan, EW, Wei, L, Wei, Y   +5 more
core   +1 more source

Engineered Transformer Base Editor with Enhanced Editing Efficiency

Advanced Science, EarlyView.
A highly efficient transformer base editor system achieves robust genomic editing in a humanized mouse model. This work establishes a versatile and translatable platform, opening new avenues for precision gene therapy. ABSTRACT Canonical cytosine base editors (CBEs) achieve precise C‐to‐T conversions without inducing DNA double‐strand breaks (DSBs ...
Bowen Chen, Letong Liang, Rui Xu, Tianyi Wang, Hongyan Chen, Daru Lu   +5 more
wiley   +1 more source

Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. [PDF]

, 2012
Proprotein convertase subtilisin/kexin-9 (PCSK9) enhances the degradation of hepatic low-density lipoprotein receptor (LDLR). Deletion of PCSK9, and loss-of-function mutants in humans result in lower levels of circulating LDL-cholesterol and a strong ...
Claudio Mapelli (148072), Katherine A. Hajjar (148095), Maxime Denis, Hanny Wassef, Steve Poirier (148055), Hanny Wassef (148085), Gaétan Mayer (148105), Gaétan Mayer, Steve Poirier, Bowman Miao, Rex Parker (148062), Annik Prat, Katherine A Hajjar, Jean Davignon, Nabil G Seidah, Bowman Miao (148067), Maxime Denis (148057), Claudio Mapelli, Annik Prat (148078), Rex Parker, Nabil G. Seidah (148050), Jean Davignon (148091)   +21 more
core   +1 more source

A Case of Familial Hypercholesterolemia and Cerebrotendinous Xanthomatosis With Multiple Giant Xanthomas

Annals of Internal Medicine: Clinical Cases
A 56-year-old woman was referred to our hospital for evaluation of multiple infectious giant xanthomas on her upper and lower limbs. She was initially diagnosed with heterozygous familial hypercholesterolemia with a proprotein convertase subtilisin/kexin
Tatsuya Maruhashi, Shogo Matsui, Shinji Kishimoto, Masato Kajikawa, Yukihito Higashi   +4 more
doaj   +1 more source

Ilexoside K Ameliorates Atherosclerosis by Suppressing CD72hi Macrophages and Blocking CXCL12–CXCR4 Axis to Inhibit Endothelial Pyroptosis

Advanced Science, EarlyView.
CD72hi macrophages drive endothelial pyroptosis and accelerate atherosclerosis through CXCL12–CXCR4‐mediated immune–vascular crosstalk. Ilexoside K suppresses this pathogenic communication by modulating CXCR4‐dependent endothelial responses, reducing inflammation and plaque progression. These findings reveal a macrophage–endothelial regulatory axis and
Xingling He, Sijing Li, Jiahui Chen, Liyu Lin, Xinyu Li, Xiaojiao Zhang, Yihui Zhang, Xingling Chen, Jinjian Guo, Zhongqi Yang, Lu Lu, Shihao Ni   +11 more
wiley   +1 more source

Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis

, 2021
PURPOSE: PCSK9 might affect central nervous system development, neuronal apoptosis, and differentiation. We investigate the neurocognitive adverse events associated with the use of PCSK9 inhibitors (alirocumab and evolocumab) using pharmacovigilance ...
VEYRAC, Gwenaelle, BEZIN, Julien, GOUVERNEUR, Amandine, BEGAUD, Bernard, SALEM, Joe-Elie, SANCHEZ-PENA, Paola   +5 more
core   +1 more source

Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified

Therapeutics and Clinical Risk Management, 2019
Seth J Baum,1,2 Rolin L Wade,3 Pin Xiang,4 Jorge Arellano,4 Cesar Cerezo Olmos,5 Sasikiran Nunna,6 Chi-Chang Chen,6 Cathryn M Carter,7 Nihar R Desai8 1Department of Integrated Medical Sciences, Charles E Schmidt College of Medicine, Florida Atlantic ...
Baum SJ, Wade RL, Xiang P, Arellano J, Cerezo Olmos C, Nunna S, Chen CC, Carter CM, Desai NR   +8 more
doaj  

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9

Journal of Lipid Research, 2008
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has gained attention as a key regulator of serum low density lipoprotein cholesterol (LDL-C) levels. This novel protease causes the degradation of hepatic low density lipoprotein receptors. In humans,
Holly E. Careskey, R. Aleks Davis, William E. Alborn, Jason S. Troutt, Guoqing Cao, Robert J. Konrad   +5 more
doaj   +1 more source

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]

Journal of Lipid Research, 2014
LDL cholesterol (LDL-C) contributes to coronary heart disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases LDL-C by inhibiting LDL-C clearance.
Brandon Ason, José W.A. van der Hoorn, Joyce Chan, Edward Lee, Elsbet J. Pieterman, Kathy Khanh Nguyen, Mei Di, Susan Shetterly, Jie Tang, Wen-Chen Yeh, Margrit Schwarz, J. Wouter Jukema, Rob Scott, Scott M. Wasserman, Hans M.G. Princen, Simon Jackson   +15 more
doaj   +1 more source

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance

, 2022
Xiaoming Jia,1 Mahmoud Al Rifai,1 Anum Saeed,2 Christie M Ballantyne,1 Salim S Virani1,3 1Department of Medicine, Baylor College of Medicine, Houston, TX, USA; 2Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA ...
Virani SS, Ballantyne CM, Jia X, Al Rifai M, Saeed A   +4 more
core